Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------------------------------------|-----------------------------------| | For the transition period from | __ ...

Revenue Growth - Revenue increased 9% to $54.9 billion in Q3 FY24 compared to Q3 FY23[1][3] - Revenue for Q3 2024 increased by 9% to $54.911 billion compared to $50.487 billion in Q3 2023[20] - Year-to-date revenue for 2024 increased by 10% to $167.119 billion compared to $151.559 billion in 2023[20] - Pharmaceutical and Specialty Solutions segment revenue increased 9% to $50.7 billion in Q3 FY24[5] - Other segment revenue increased 14% to $1.2 billion in Q3 FY24[8] - Pharmaceutical and Solutions segment revenue grew 9% YoY to $50,651 million in Q3 2024[26] - Global Medical Products and Distribution segment revenue grew 4% YoY to $3,113 million in Q3 2024[26] - Year-to-date revenue for Pharmaceutical and Solutions segment grew 11% YoY to $154,524 million[27] - Year-to-date revenue for Global Medical Products and Distribution segment grew 1% YoY to $9,264 million[27] Non-GAAP Financial Performance - Non-GAAP operating earnings increased 10% to $666 million in Q3 FY24[1][3] - Non-GAAP diluted EPS increased 20% to $2.08 in Q3 FY24[1][3] - Fiscal year 2024 non-GAAP EPS guidance raised to $7.30 to $7.40[1][9] - Preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50[1][10] - Non-GAAP net earnings for Q3 2024 were $509 million, a 14% increase YoY[32] - Non-GAAP diluted EPS for Q3 2024 was $2.08, a 20% increase YoY[32] - Non-GAAP operating earnings for the nine months ended March 31, 2024, were $1,799 million, with a 20% effective tax rate, resulting in a diluted EPS of $5.62, a 33% increase year-over-year[35] - Non-GAAP operating earnings for the nine months ended March 31, 2023, were $1,497 million, with a 21% effective tax rate, resulting in a diluted EPS of $4.24[35] Segment Performance - Pharmaceutical and Specialty Solutions segment profit growth outlook updated to 8.5% to 9.5% for FY24[9] - Global Medical Products and Distribution segment profit increased $66 million to $20 million in Q3 FY24[6][7] - Global Medical Products and Distribution segment profit expected to be ~$175 million in FY25[11] - Impairment charges for the GMPD segment were $90 million in Q3 2024 and $671 million year-to-date[20] - The company recognized a cumulative pre-tax goodwill impairment charge of $671 million related to the GMPD segment for the nine months ended March 31, 2024, with an estimated net tax benefit of $56 million[35] - The company recognized a cumulative pre-tax goodwill impairment charge of $863 million related to the GMPD segment for the nine months ended March 31, 2023, with a net tax benefit of $68 million[35] GAAP Financial Performance - Net earnings for Q3 2024 decreased by 25% to $259 million compared to $347 million in Q3 2023[20] - GAAP net earnings for Q3 2024 were $258 million, a 25% decrease YoY[31] - GAAP diluted EPS for Q3 2024 was $1.05, a 22% decrease YoY[31] - GAAP operating earnings for the nine months ended March 31, 2024, were $835 million, with a 42% effective tax rate, resulting in a diluted EPS of $2.49[35] - GAAP operating earnings for the nine months ended March 31, 2023, were $590 million, with a 36.7% effective tax rate, resulting in a diluted EPS of $1.23[35] Cash Flow and Liquidity - Cash and equivalents decreased to $3.718 billion as of March 31, 2024, from $4.043 billion as of June 30, 2023[22] - Net cash provided by operating activities in Q3 2024 was -$49 million, compared to $1,361 million in Q3 2023[25] - GAAP net cash provided by operating activities for the nine months ended March 31, 2024, was $1,685 million, compared to $1,981 million for the same period in 2023[37] - Non-GAAP adjusted free cash flow for the nine months ended March 31, 2024, was $2,128 million, compared to $2,090 million for the same period in 2023[37] - The company excluded $246 million in payments related to litigation recoveries/charges from non-GAAP adjusted free cash flow for the third quarter of 2024[37] Balance Sheet Changes - Total current assets increased to $35.734 billion as of March 31, 2024, from $33.833 billion as of June 30, 2023[22] - Total liabilities increased to $45.880 billion as of March 31, 2024, from $43.417 billion as of June 30, 2023[23] - Accounts payable increased to $32.089 billion as of March 31, 2024, from $29.813 billion as of June 30, 2023[23] - Total shareholders' deficit increased to $3.262 billion as of March 31, 2024, from $2.851 billion as of June 30, 2023[23] Gross Margin and Operating Earnings - Gross margin for Q3 2024 increased by 9% to $1.947 billion compared to $1.785 billion in Q3 2023[20] - Non-GAAP gross margin excludes LIFO charges/(credits)[44] - Non-GAAP SG&A excludes state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs[44] - Non-GAAP operating earnings exclude LIFO charges/(credits), state opioid assessment, shareholder cooperation agreement costs, restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, net, and litigation (recoveries)/charges, net[44] Non-GAAP Adjustments and Definitions - The company's non-GAAP financial measures exclude items such as LIFO charges, state opioid assessments, shareholder cooperation agreement costs, restructuring costs, and acquisition-related costs to provide a clearer view of ongoing business performance[39] - Segment Profit is calculated as segment revenue minus segment cost of products sold and segment distribution, selling, general and administrative expenses[44] - Segment Profit margin is derived by dividing segment profit by segment revenue[44] - Non-GAAP earnings before income taxes exclude LIFO charges/(credits), state opioid assessment, shareholder cooperation agreement costs, restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, net, litigation (recoveries)/charges, net, and loss on early extinguishment of debt[44] - Non-GAAP net earnings attributable to Cardinal Health, Inc. exclude LIFO charges/(credits), state opioid assessment, shareholder cooperation agreement costs, restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, net, litigation (recoveries)/charges, net, and loss on early extinguishment of debt, each net of tax[44] - Non-GAAP effective tax rate adjusts for the tax impacts of LIFO charges/(credits), state opioid assessment, shareholder cooperation agreement costs, restructuring and employee severance, amortization and other acquisition-related costs, impairments and (gain)/loss on disposal of assets, net, litigation (recoveries)/charges, net, and loss on early extinguishment of debt[44] - Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. is calculated by dividing non-GAAP net earnings attributable to Cardinal Health, Inc. by diluted weighted-average shares outstanding[44] - Non-GAAP adjusted free cash flow is net cash provided by/(used in) operating activities less payments related to additions to property and equipment, excluding settlement payments and receipts related to litigation (recoveries)/charges, net, or other significant and unusual or non-recurring cash payments or receipts[44]

Cardinal Health, Inc. (NYSE:CAH) Q2 2024 Earnings Conference Call February 1, 2024 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JP Morgan Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Erin Wright - Morgan Stanley Allen Lutz - Bank of America Kevin Caliendo - UBS George Hill - Deutsche Bank Stephen Baxter - Wells F ...

Q2 FY24 Earnings Cardinal Health, Inc. February 1, 2024 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted ...

Cardinal Health, Inc. (NYSE:CAH) Q1 2024 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Matt Sims - VP of IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JPMorgan Eric Percher - Nephron Research Kevin Caliendo - UBS Erin Wright - Morgan Stanley George Hill - Deutsche Bank Elizabeth Anderson - Evercore Daniel Grosslight - Citi Charles Rhyee - TD Cowen Allen Lutz - Bank of America Operator Good day, and welcome to today's First Quarter Financial Year 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other j ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_0dfd0b29486237e1091cb07603273918.html ...

Q4 FY23 Earnings Cardinal Health, Inc. August 15, 2023 ...

Financial Data and Key Metrics Changes - Cardinal Health reported a record financial performance for fiscal year 2023, achieving a non-GAAP EPS of $5.79, reflecting a 14% growth year-over-year [6][10] - The company generated $205 billion in revenue for fiscal 2023, a 13% increase compared to the previous year, with gross margin rising 5% to $6.9 billion [15][16] - Adjusted free cash flow reached $2.8 billion, with a strong cash position of $4 billion at year-end [17][18] Business Line Data and Key Metrics Changes - In the Pharma segment, revenue increased by 15% to $49.7 billion in Q4, with segment profit rising 12% to $504 million, driven by strong performance in generics and specialty products [10][11] - The Medical segment reported flat revenue of $3.8 billion in Q4 but achieved a profit of $82 million, a significant improvement from a loss in the prior year [12][13] - For the full year, Pharma segment profit increased 13% to $2 billion, while Medical segment profit decreased 49% to $111 million due to lower volumes and unfavorable sales mix [16] Market Data and Key Metrics Changes - The company noted broad-based strength in pharmaceutical demand across various product categories, including brand, specialty, consumer health, and generics [10][11] - The Medical segment experienced a decrease in products and distribution sales, partially offset by growth in at-home solutions [12] Company Strategy and Development Direction - Cardinal Health is focused on three strategic imperatives: enhancing the Pharma segment's resilience, executing the Medical Improvement Plan, and maximizing shareholder value [7][9] - The company is investing in its Nuclear & Precision Health Solutions business and has launched the Navista Network to support community oncologists [8][27] - Cardinal Health aims to achieve a 12% to 14% EPS growth CAGR from fiscal 2024 to 2026, building on a higher fiscal 2023 baseline [22][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate inflation and supply chain challenges, with expectations of improved profitability in fiscal 2024 [31][36] - The company anticipates continued growth in the Pharma segment, particularly from GLP-1 medications, while the Medical segment is expected to improve sequentially throughout the year [19][21] Other Important Information - Cardinal Health completed a merger with BlackRock's Transaction Data Systems, which is expected to accelerate future growth [9] - The company returned over $2.5 billion to shareholders, including a $500 million accelerated share repurchase program [18] Q&A Session Summary Question: Clarification on GLP-1 impact on revenue guidance - Management confirmed that the revenue guidance increase is primarily due to GLP-1 medications, which are lower margin but contribute to overall revenue growth [40] Question: Core performance metrics for Medical segment - Management clarified that the core performance for the Medical segment was approximately $60 million, with additional contributions from seasonality and one-time items [42][43] Question: Progress on Navista offering - Management highlighted that the Navista Network is being built on existing capabilities and is focused on supporting community oncologists, with new leadership and customer engagement initiatives in place [51][52] Question: Capital allocation priorities for fiscal 2024 - Management indicated a disciplined approach to capital allocation, focusing on organic growth investments, litigation payments, and shareholder returns [76]